Clinical Trials Browser

Completed × Triple Negative Breast Neoplasms × durvalumab × Clear all

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04504669 2024-11-05

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02527434 2023-11-15

Study of Tremelimumab in Patients With Advanced Solid Tumors

Phase 2 Completed

64 enrolled 22 charts

Breast

Triple Negative Breast Neoplasms

NCT03167619 2022-09-13

DORA

Phase 2 Completed

45 enrolled 19 charts

Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03544125 2020-11-20

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Phase 1 Completed

3 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Phase 1 Completed

32 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Clinical Trials

B-IMMUNE

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Study of Tremelimumab in Patients With Advanced Solid Tumors

DORA

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors